This week Therapeutics initative podcast deals with NSAIDS:

NSAIDS: Considering the Risks and Benefits (Therapeutics Initiative Podcast – December 10th)

In our 33rd episode we follow-up our discussion of osteoarthritis by examining the risks and benefits of oral anti-inflammatories including Cox-2 inhibitors. We review the effects on pain relief and the theory of anti-inflammation. We discuss the possible gastrointestinal effects and possible approaches to reduce the risk. We consider the cardiovascular risks and debate the choices in prescribing. We finish by struggling to get in the last word.

Listen now:

Download podcast Subscribe with iTunes Disclaimer Show Notes

Drugs related to this podcast


Salicylates: Acetylsalicylic acid (Aspirin), Amoxiprin, Benorylate/Benorilate, Choline magnesium salicylate, Diflunisal, Ethenzamide, Faislamine, Methyl salicylate, Magnesium salicylate, Salicyl salicylate, Salicylamide.

Arylalkanoic acids : Diclofenac, Aceclofenac, Acemethacin, Alclofenac, Bromfenac,
Etodolac, Indomethacin, Nabumetone, Oxametacin, Proglumetacin, Sulindac, Tolmetin.

2-Arylpropionic acids (profens): Ibuprofen, Alminoprofen, Benoxaprofen (withdrawn from the market), Carprofen, Dexibuprofen, Dexketoprofen, Fenbufen, Fenoprofen, Flunoxaprofen, Flurbiprofen, Ibuproxam, Indoprofen, Ketoprofen (Actron, at least, has been withdrawn from the market.), Ketorolac, Loxoprofen, Naproxen, Oxaprozin, Pirprofen, Suprofen, Tiaprofenic acid

N-Arylanthranilic acids (fenamic acids): Mefenamic acid, Flufenamic acid, Meclofenamic acid, Tolfenamic acid

Pyrazolidine derivatives: Phenylbutazone, Ampyrone, Azapropazone, Clofezone, Kebuzone, Metamizole, Mofebutazone, Oxyphenbutazone, Phenazone, Sulfinpyrazone

Oxicams: Piroxicam, Droxicam, Lornoxicam, Meloxicam, Tenoxicam

COX-2 inhibitors: Celecoxib (FDA alert), Etoricoxib (FDA withdrawn), Lumiracoxib TGA cancelled registration, Parecoxib FDA withdrawn, Rofecoxib (withdrawn from market), Valdecoxib (withdrawn from market )

Sulphonanilides: Nimesulide (banned by several countries for the potential risk of hepatotoxicity)

Source: Episode 33: NSAIDS: Considering the Risks and Benefits (Therapeutics Initiative Podcast РDecember 10th)

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos